Literature DB >> 30693992

Human T lymphotropic virus type 1 and risk of cardiovascular disease: High-density lipoprotein dysfunction versus serum HDL-C concentrations.

Sara Samadi1,2,3, Samaneh Abolbashari1,2, Zahra Meshkat1, Amir Hooshang Mohammadpour4,5, Theodoros Kelesidis6, Aida Gholoobi1, Mehrane Mehramiz1, Mahla Tabadkani3, Fatemeh Sadabadi1, Razieh Dalirfardouei7, Gordon A Ferns8, Majid Ghayour-Mobarhan3, Amir Avan3.   

Abstract

High-density lipoprotein (HDL) is thought to be protective against cardiovascular disease (CVD), and HDL dysfunction is considered to be a risk factor for CVD. It is unclear whether there is an association between Human T lymphotropic virus type 1 (HTLV1) infection and CVD risk. We have assessed HDL lipid peroxidation (HDLox) as a marker of HDL dysfunction and CVD risk in a subgroup of the MASHAD cohort study. One hundred and sixty two individuals including 50 subjects positive for HTLV1 infection and 112 individuals negative for HTLV1 infection were recruited. Anthropometric and biochemical parameters including serum hs-CRP, fasted lipid profile (HDL-C, LDL, triglycerides, and cholesterol), and fasting blood glucose were determined. Serum HDLox was also measured in the study participants. Multivariate analyses were used to evaluate the association between serum HDLox and HTLV1 infection. None of the traditional CVD risk factors were associated with HTLV1 infection, including serum HDL-C. However, serum HDLox was independently associated with the presence of HTLV1 infection. Logistic regression analysis showed that subjects who were positive for HTLV1 infection were also significantly more likely than uninfected individuals to have higher HDLox (odds ratio 9.35, 95%CI: 3.5-24.7; P < 0.001). HDLox was increased approximately 20% (P < 0.001) in infected subjects compared to the uninfected group. Serum HDLox is a marker of CVD risk factor and increased in individuals affected by HTLV1 infection compared to healthy subjects.
© 2019 BioFactors, 45(3):374-380, 2019. © 2019 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  HDL lipid peroxidation; HDLox; HTLV1 infection; high-density lipoprotein; viral infectious disease

Mesh:

Substances:

Year:  2019        PMID: 30693992      PMCID: PMC6548577          DOI: 10.1002/biof.1489

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  39 in total

Review 1.  HTLV-1 infections.

Authors:  C R Bangham
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

Review 2.  Global epidemiology of HTLV-I infection and associated diseases.

Authors:  Fernando A Proietti; Anna Bárbara F Carneiro-Proietti; Bernadette C Catalan-Soares; Edward L Murphy
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 3.  The double jeopardy of HDL.

Authors:  Mohamad Navab; G M Ananthramaiah; Srinivasa T Reddy; Brian J Van Lenten; Benjamin J Ansell; Susan Hama; Greg Hough; Eugene Bachini; Victor R Grijalva; Alan C Wagner; Zory Shaposhnik; Alan M Fogelman
Journal:  Ann Med       Date:  2005       Impact factor: 4.709

Review 4.  Human T-lymphotropic virus 1: recent knowledge about an ancient infection.

Authors:  Kristien Verdonck; Elsa González; Sonia Van Dooren; Anne-Mieke Vandamme; Guido Vanham; Eduardo Gotuzzo
Journal:  Lancet Infect Dis       Date:  2007-04       Impact factor: 25.071

5.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

6.  HTLV-I/II prevalence in different geographic locations.

Authors:  Hans Vrielink; Henk W Reesink
Journal:  Transfus Med Rev       Date:  2004-01

Review 7.  The role of dysfunctional HDL in atherosclerosis.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

Review 8.  Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.

Authors:  Weerapan Khovidhunkit; Min-Sun Kim; Riaz A Memon; Judy K Shigenaga; Arthur H Moser; Kenneth R Feingold; Carl Grunfeld
Journal:  J Lipid Res       Date:  2004-04-21       Impact factor: 5.922

9.  Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!

Authors:  Sander I van Leuven; Raaj R Sankatsing; Joost N Vermeulen; John J P Kastelein; Peter Reiss; Erik S G Stroes
Journal:  Curr Opin HIV AIDS       Date:  2007-07       Impact factor: 4.283

Review 10.  Systemic inflammation as a risk factor for atherothrombosis.

Authors:  S I van Leuven; R Franssen; J J Kastelein; M Levi; E S G Stroes; P P Tak
Journal:  Rheumatology (Oxford)       Date:  2007-08-16       Impact factor: 7.580

View more
  1 in total

1.  The effect of HTLV1 infection on inflammatory and oxidative parameters in the liver, kidney, and pancreases of BALB/c mice.

Authors:  Saeed Niazmand; Arezoo Gowhari Shabgah; Sara Hosseinian; Jamshid Gholizadeh Navashenaq; Ali Kamali; Mohammad Reza Khazdair; Yousef Baghcheghi; Mahdiyeh Hedayati-Moghadam
Journal:  Physiol Rep       Date:  2022-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.